Are Peptides Legal in the US? Research Peptides and the 2026 FDA Rules

For laboratory research use only. Not for human or animal use. Legal notice · This is general information, not legal advice.
Are peptides legal? In the US, the answer comes in three parts. Some peptides are FDA-approved drugs, available by prescription, while others can be compounded by licensed pharmacies, within limits the FDA sets. And most of what labs call research peptides are legal only as laboratory reagents, sold and used for qualified study.
The year 2026 rearranged the middle part faster than any year before it. Public remarks from the HHS Secretary in February were followed by an April Federal Register notice, a July advisory committee vote, and a round of August warning letters to online sellers. This guide covers each legal channel, every dated 2026 change, buying online, controlled-substance status, state rules, imports, enforcement, and sport.
Contents
- Quick answer: are peptides legal in the US?
- Is it about the peptide or how it’s sold?
- The three legal channels for peptides in the US
- Which peptides are legal in the US?
- What changed for peptides in 2026?
- Which peptides did the FDA committee review in July 2026?
- Is it legal to buy peptides online in the US?
- Are peptides controlled substances or steroids?
- Do peptide laws differ by state?
- Importing peptides: customs and FDA rules
- Can a peptide seller get in trouble?
- Are peptides banned in sport?
- How a compliant research peptide supplier operates
- Frequently asked questions
- The bottom line
Quick Answer: Are Peptides Legal in the US?
Peptides are legal in the US through three routes: FDA-approved prescription drugs, pharmacy compounding of bulk substances the FDA permits, and Research Use Only supply for laboratory study. Research peptides such as BPC-157 and TB-500 can be sold and bought only for qualified lab research, while marketing or selling them for human use breaks the FD&C Act.
✔ Legal for laboratory research when labeled and sold as Research Use Only
✔ Unlawful to market or sell unapproved peptides for human use
✔ The July 2026 FDA advisory vote approved no peptide as a drug
| Lawful | Unlawful |
| RUO-labeled peptides sold to researchers for lab work | Selling unapproved peptides for human use |
| Product pages with identity, purity and storage only | Dosing, administration or reconstitution instructions |
| A batch COA with every lot | Health claims and testimonials |
| Approved peptide drugs dispensed by prescription | Bundling administration supplies or other human-use supplies with RUO products |
The right-hand column comes almost word for word from what the FDA has cited in its 2026 letters, which makes it a useful checklist for anyone judging a seller.
Is It About the Peptide or How It’s Sold?
US law judges a peptide by how it’s labeled, marketed and sold. One vial can be a lawful research reagent or an unapproved new drug, and the label, the marketing and the buyer decide which. The molecule alone rarely settles the question.
The rule behind this is intended use. Under 21 CFR 201.128, the FDA reads a product’s intended use from the objective intent of the people selling it: labeling, advertising, website copy, social posts, even what customer support says in reply to a question. A Research Use Only label is one piece of that record. When everything else around the sale points to use in people, the FDA treats the label as outweighed.
The agency spelled that out in 2026. A warning letter dated August 24, 2026 told one seller that “evidence obtained from your website establishes that your products are intended to be drugs for human use,” and said that its site, taken as a whole, gave buyers what they needed to prepare a drug for human administration. The letters of that round cited:
- dosing charts and reconstitution calculators
- health or outcome claims on product pages
- before-and-after content and testimonials
- administration supplies or bacteriostatic water bundled with peptide vials
The final section of this guide turns those findings into a checklist for a compliant supplier.
The Three Legal Channels for Peptides in the US
Peptides reach the US market through three legally separate channels: FDA-approved prescription drugs, peptides compounded by licensed pharmacies under Section 503A or 503B, and research-use-only compounds sold for laboratory study. Research peptides belong only in the third.
| FDA-approved drugs | Compounded (503A / 503B) | Research Use Only | |
| Legal basis | New drug approval (NDA / BLA) | FD&C Act §503A / §503B | Sold as laboratory reagents |
| Who supplies | Pharmacies | Compounding pharmacies and outsourcing facilities | Research suppliers |
| Prescription | Required | Required (503A is patient-specific) | Not applicable: lab use only |
| Human use | Yes, as labeled | Yes, by prescription | No |
| Where to check status | Drugs@FDA | 503A Bulks List; FDA Category 1 and 2 pages | Supplier’s RUO label and batch COA |
Compounding itself happens in two kinds of facility. A 503A pharmacy, or a physician, compounds for an individual patient against a prescription, and may only use bulk substances that meet the statute’s tests, such as appearing on the 503A Bulks List. A 503B outsourcing facility registers with the FDA, works under drug manufacturing standards and draws on a separate list of bulk substances with a clinical need. Almost every 2026 headline about peptides concerns the 503A side.
Which Peptides Are Legal in the US?
FDA-approved peptide drugs are legal by prescription, and the official record of them is kept in the FDA’s Drugs@FDA database. Research peptides such as BPC-157, TB-500, KPV and MOTS-c have no FDA approval. They can be sold and bought only for laboratory research.
Three checks answer the question for any named peptide:
- Search Drugs@FDA. A match means an approved drug, available by prescription as labeled.
- Check the 503A Bulks List and the FDA’s Category 1 and Category 2 pages. These show whether pharmacies may compound it.
- If both come back empty, the compound can only be supplied as a research reagent.
That three-step routine is more reliable than any “list of legal peptides” online, because the FDA pages change and copied lists don’t.
What Changed for Peptides in 2026?
In 2026 the FDA moved a set of peptides off its Category 2 compounding list, its advisory committee reviewed seven peptides in July, and it sent warning letters to online sellers in August. None of those steps approved a peptide as a drug or changed the rules for research supply.
| Date | What happened | Source |
| September 29, 2023 | FDA placed a group of peptide bulk substances in Category 2 | FDA Category 2 page |
| February 27, 2026 | The HHS Secretary said in public remarks that about 14 of 19 restricted peptides would move back toward compounding eligibility | Secondary reports, e.g. AJMC; no formal HHS release found |
| April 2026 | FDA removed 12 peptides from Category 2 after their nominators withdrew them, and scheduled advisory committee review | Federal Register 2026-07361, April 16, 2026; FDA Category 2 page |
| July 23-24, 2026 | The advisory committee met over two days to vote on seven peptides nominated for the 503A Bulks List | FDA Law Blog |
| August 24, 2026 | FDA warning letters to online peptide sellers (reports differ on whether four or five were sent) | FDA warning letter |
| October 14, 2026 | An interim policy on compounding certain peptides went to the White House budget office (OMB) for review; still unissued on October 16 | Holland & Knight |
| October 25, 2026 | No Federal Register rule adding any peptide to the 503A Bulks List | Federal Register |
What Is FDA Category 2?
Category 2 is the FDA’s interim list of bulk substances that compounding pharmacies shouldn’t use while the agency evaluates concerns raised about them. Category 1 substances, by contrast, can be compounded during their review.
Leaving Category 2 is a procedural step. A substance still needs Category 1 status or a place on the 503A Bulks List before a 503A pharmacy can use it. On the FDA’s Category 2 page, content current as of April 22, 2026, four peptides remain: GHRP-2, GHRP-6, and ipamorelin acetate, all flagged for 503B facilities, plus kisspeptin-10, flagged for 503A pharmacies.

US peptide status board as of October 25, 2026, showing 14 substances in FDA Category 2, four of them peptides, 17 withdrawn nominations, and no peptides added to the 503A list or approved
Did the FDA “Unban” Peptides?
No. Committee votes are advisory, a listing needs notice-and-comment rulemaking, and even a listing would allow only prescription compounding. None of it amounts to drug approval, and none of it changes research supply.
Which Peptides Did the FDA Committee Review in July 2026?
Across two days, July 23 and 24, 2026, seven peptides went before the FDA’s Pharmacy Compounding Advisory Committee as candidates for the 503A Bulks List: BPC-157, KPV, TB-500 and MOTS-c on the first day, then DSIP (emideltide), Semax and Epitalon on the second. Its votes are advisory.
| Peptide | Day | Committee outcome | Research overview |
| BPC-157 | 1 | Recommended | BPC-157 research overview |
| KPV | 1 | Recommended | KPV research overview |
| TB-500 | 1 | Recommended | TB-500 research overview |
| MOTS-c | 1 | Recommended | MOTS-c research overview |
| DSIP (emideltide) | 2 | Not recommended | DSIP research overview |
| Semax | 2 | Recommended | Semax vs Selank |
| Epitalon | 2 | Recommended | Epitalon research overview |
Each nomination was reviewed for specific proposed compounding uses, listed in the FDA briefing documents. FDA staff had proposed that none of the seven be added. The panel recommended six and declined one, and, in the FDA Law Blog’s words, “the vote is advisory and one input among many.” Final decisions come through notice-and-comment rulemaking, and no such rule had appeared in the Federal Register as of October 25, 2026.

FDA advisory committee votes from July 2026 on seven peptides, with six recommended for the 503A Bulks List and DSIP declined
Is It Legal to Buy Peptides Online in the US?
Buying research peptides online is legal when a supplier labels them Research Use Only and sells them for laboratory research. Research-use supply doesn’t cover buying unapproved peptides for personal or human use, and selling for that purpose is unlawful.
A compliant online sale has four visible parts:
- Label: the exact RUO statement on the vial, the product page, and the invoice.
- Product page: identity, purity, and storage only, with nothing about effects in people.
- Buyer: confirms the material is for laboratory research.
- Paperwork: a batch-specific certificate of analysis that matches the lot.
Ordering details for US labs and institutions are on our research peptides USA page. Orders from overseas suppliers add customs review, covered in the import section below.
Are Peptides Controlled Substances or Steroids?
Most research peptides aren’t controlled substances under the federal Controlled Substances Act, and they aren’t anabolic steroids. Their labeling and sale fall under the FDA. Human growth hormone carries its own separate federal distribution rule.
The DEA’s schedules, published in 21 CFR Part 1308, list substances by abuse potential, and the common research peptides discussed in this guide don’t appear on them. Anabolic steroids are a Schedule III class built on a four-ring steroid skeleton, chemically unrelated to amino-acid chains. Human growth hormone is the well-known special case: 21 U.S.C. §333(e) makes distributing it, or possessing it with intent to distribute, a federal offense outside the narrow uses the statute authorizes. States can layer their own rules on top, which the next section covers.
Do Peptide Laws Differ by State?
Federal law sets the baseline through the FD&C Act and the Controlled Substances Act. States regulate pharmacy practice and compounding, and some add rules of their own, so the right place to check a specific compound is the state board of pharmacy.
What states typically regulate:
- pharmacy and outsourcing-facility licensing
- compounding standards and inspections
- who may prescribe, and under what conditions
The National Association of Boards of Pharmacy keeps a directory of state boards, and each board publishes its own rules; the California State Board of Pharmacy is one example. This guide makes no state-by-state claims, because the official sources change and only they are authoritative.
Importing Peptides: Customs and FDA Rules
Imported peptides are reviewed by both the FDA and US Customs and Border Protection. Under Section 801(a) of the FD&C Act, shipments that appear intended for human use or lack proper labeling can be detained or refused entry.
The legal basis is 21 U.S.C. §381: the FDA can refuse admission to an article that appears adulterated, misbranded, or an unapproved new drug. For repeat problems, the agency issues import alerts, which let CBP detain a supplier’s shipments without physical examination. Country of origin decides little on its own. Labeling, paperwork, and the apparent use of the goods decide more, which is why a shipment travelling with its batch documentation and RUO labeling has the cleaner path. Labs ordering from outside the US can read our guide to ordering outside the US.
Can a Peptide Seller Get in Trouble?
Yes. Sellers that market unapproved peptides for human use face FDA warning letters, import alerts, product seizures, and court injunctions. In 2026 the FDA cited sellers for dosing guidance, reconstitution calculators, health claims, and human-use bundles, research-use labels notwithstanding.
| Tool | What it does |
| Warning letter | Formal notice of violations, published on FDA.gov |
| Import alert | Lets CBP detain a supplier’s shipments without physical examination |
| Seizure | Court-ordered removal of violative product |
| Injunction | Court order stopping the business practice |
| FTC action | Enforcement against deceptive health claims in advertising under the FTC Act |
The August 2026 letters gave each recipient 15 business days to respond. Every one of those sellers carried a research-use disclaimer somewhere on its labeling, and the FDA looked past it to the website as a whole.
Are Peptides Banned in Sport?
Many research peptides appear on the World Anti-Doping Agency’s Prohibited List. WADA bans non-approved substances under S0 and peptide hormones and growth factors under S2, at all times.
| Category | Covers | Named examples on the 2026 list |
| S0 | Non-approved substances | BPC-157 |
| S2.2.4 | GHRH and its analogues | CJC-1295 |
| S2.3 | Growth factors and growth factor modulators | Thymosin-β4 and its derivatives, e.g. TB-500 |
The 2026 WADA Prohibited List has been in force since January 1, 2026. WADA approved the 2027 list on September 10, 2026, and it takes effect on January 1, 2027.
How a Compliant Research Peptide Supplier Operates
A compliant US research supplier labels every product Research Use Only, makes no health or therapeutic claims, publishes batch-specific certificates of analysis, and sells to researchers for laboratory study.
Use this checklist to judge any supplier, including us:
- RUO labeling on every vial, product page, and invoice
- no human-use claims on the website, social media or affiliate content
- independent third-party batch testing
- lot traceability from certificate to vial
- storage guidance for lyophilized material
- buyer confirmation of research purpose
Each Cellugenix batch goes to an independent lab, and the resulting report lists HPLC purity (see each batch result) alongside the amount measured in the vial. The reports don’t include mass spectrometry, so labs that need identity confirmation add it themselves. Current reports can be opened in the COA library. Two explainers go deeper: third-party lab testing explained and how to evaluate a research peptide vendor. Compounds supplied for laboratory research are listed on our research peptides in the USA page.
Frequently Asked Questions
What does “Research Use Only” mean on a peptide?
It means the material is supplied for laboratory study only, never for diagnosis, treatment, or use in people or animals. The FDA reads the label alongside the seller’s marketing, so an RUO statement holds up only when the website, product pages, and support all match it.
Are peptides FDA-approved?
Some peptide drugs are FDA-approved and available by prescription; the full record is in the FDA’s Drugs@FDA database. Research peptides such as BPC-157, TB-500, and MOTS-c have no FDA approval and are supplied only for laboratory study under research-use-only labeling.
Did the FDA ban peptides in 2026?
No. The 2026 steps ran the other way: a set of peptides left Category 2 in April, and an advisory committee recommended six for the 503A Bulks List in July. Those recommendations are advisory, and the rules for research supply didn’t change.
Can BPC-157 be compounded in 2026?
Not yet. BPC-157 came off Category 2 in April 2026, yet it’s still absent from both the 503A Bulks List and Category 1. The July 2026 committee recommendation is advisory, and any listing needs FDA rulemaking, which hadn’t been published as of October 25, 2026.
Are peptides controlled substances?
Most aren’t. Common research peptides don’t appear on the DEA’s Controlled Substances Act schedules, and the FDA regulates how they’re labeled and sold. Human growth hormone is the main exception, with its own federal distribution rule under 21 U.S.C. §333(e).
Are peptide laws different by state?
Yes, in part. Federal law sets the baseline, while each state regulates pharmacy practice, compounding, and prescribing through its board of pharmacy. For any specific compound, the state board’s published rules are the authoritative source, and a licensed attorney can apply them.
Are research peptides legal in Canada or Europe?
Canada regulates drugs under the Food and Drugs Act, and EU countries apply national rules alongside EU medicines law, so the answer depends on the country. In Canada, injectable peptides are generally handled as prescription drugs. Authorized drugs carry an eight-digit Drug Identification Number, and Health Canada has stated that products labelled for research use only are not intended for human consumption. In November 2026 it issued a public advisory about unauthorized injectable peptides sold online and took enforcement action against two Canadian online retailers. Our guide to ordering outside the US covers shipping and paperwork.
The Bottom Line
Research peptides are legal in the US for laboratory research when they’re labeled and sold as Research Use Only. Selling them for human use breaks federal law, and the FDA’s 2026 letters show it reads the whole website to decide. The year’s compounding process concerns prescription pharmacies, and it approved no peptide as a drug.
We review this guide whenever the FDA acts. Last checked October 25, 2026.
Browse research compounds, each with a batch COA
For laboratory research use only. Not for human or animal use. This is general information, not legal advice. Terms
Sources
- FDA, Certain bulk drug substances for use in compounding that may present significant safety risks, content current as of April 22, 2026 (checked October 25, 2026)
- Federal Register, Pharmacy Compounding Advisory Committee notice, document 2026-07361, April 16, 2026; no final 503A rule found as of October 25, 2026
- FDA, warning letter dated August 24, 2026 (quoted)
- FDA Law Blog, PCAC day 1, July 24, 2026, and day 2, July 28, 2026
- DLA Piper, PCAC alert, July 31, 2026
- AJMC, 5 Things to Know About the FDA’s Peptide Reversal, August 21, 2026 (secondary report of the February remarks)
- Holland & Knight, peptide policy alert, October 16, 2026
- 21 CFR 201.128; FD&C Act §503A, §503B, §801(a); 21 U.S.C. §333(e)
- DEA schedules, 21 CFR Part 1308
- FDA, Drugs@FDA and import alerts
- NABP, state boards of pharmacy
- WADA, 2026 Prohibited List (S0; S2.2.4; S2.3), in force January 1, 2026; 2027 list approved September 10, 2026
For laboratory research use only. Not for human or animal use.



